EADV 2016 – METOP study in medac satellite symposium
Benefits for psoriasis practices: New phase III data shows subcutaneous methotrexate’s favorable long-term efficacy and safety profile.
Medac hosted a satellite symposium at the EADV conference 2016 in Vienna with the title METOP study – evaluation of subcutaneous methotrexate for psoriasis patients.
Satellite symposium took place on Friday 30th of September, 2016 at Hall L3, floor 1.
medac press release EADV2016